Previous 10 | Next 10 |
2024-02-05 08:31:42 ET Chenghe Acquisition ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...
- RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to acquire worldwide rights to RT-111 following a Phase 1 clinical trial that meets its primary endpoints – ...
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data support the potential for the RaniPill platform to enable oral delivery of multiple obesity treatments - SAN JOSE, Calif., Dec. 14, ...
2023-12-08 12:45:17 ET Gainers: Intensity Therapeutics ( INTS ) +100% . MBIA ( MBI ) +74% . Conduit Pharmaceuticals ( CDT ) +47% . EF Hutton Acquisition Corp I ( EFHT ) +44% . Alx Oncology Holdings ( ALXO ) +35% . View ( VI...
2023-12-08 10:43:47 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Rani Therapeutics GAAP EPS of -$0.36 misses by $0.05 Canaccord believes Rani restructuring will help speed development For further details see: ...
2023-12-06 12:46:20 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics For further details see: Rani Therapeuti...
2023-12-01 10:20:04 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Rani Therapeutics GAAP EPS of -$0.36 misses by $0.05 Canaccord believes Rani restructuring will help speed development For further details see: ...
2023-11-09 13:33:11 ET More on Rani Therapeutics Rani Therapeutics: Excellent Technology But Major Risks Ahead Canaccord believes Rani restructuring will help speed development Rani to cut 25% of workforce as it reprioritizes drug programs Seeking Alphaȁ...
Rani Therapeutics Holdings Inc. (RANI) is expected to report $-0.47 for Q3 2023
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, a RaniPill GO containing ustekinumab biosimilar CT-P43, with topline result...
News, Short Squeeze, Breakout and More Instantly...
Rani Therapeutics Holdings Inc. Company Name:
RANI Stock Symbol:
NASDAQ Market:
Rani Therapeutics Holdings Inc. Website:
SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a...
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism with bioavailability comparable to subcutaneous injection ~ ~ Rani and Pr...
2024-05-16 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...